CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, 116000, China.
Nat Commun. 2022 Apr 21;13(1):2187. doi: 10.1038/s41467-022-29846-9.
Elevated de novo lipogenesis is considered to be a crucial factor in hepatocellular carcinoma (HCC) development. Herein, we identify ubiquitin-specific protease 22 (USP22) as a key regulator for de novo fatty acid synthesis, which directly interacts with deubiquitinates and stabilizes peroxisome proliferator-activated receptor gamma (PPARγ) through K48-linked deubiquitination, and in turn, this stabilization increases acetyl-CoA carboxylase (ACC) and ATP citrate lyase (ACLY) expressions. In addition, we find that USP22 promotes de novo fatty acid synthesis and contributes to HCC tumorigenesis, however, this tumorigenicity is suppressed by inhibiting the expression of PPARγ, ACLY, or ACC in in vivo tumorigenesis experiments. In HCC, high expression of USP22 positively correlates with PPARγ, ACLY or ACC expression, and associates with a poor prognosis. Taken together, we identify a USP22-regulated lipogenesis mechanism that involves the PPARγ-ACLY/ACC axis in HCC tumorigenesis and provide a rationale for therapeutic targeting of lipogenesis via USP22 inhibition.
从头合成的脂肪生成增加被认为是肝细胞癌 (HCC) 发展的一个关键因素。在此,我们确定泛素特异性蛋白酶 22 (USP22) 是从头脂肪酸合成的关键调节因子,它通过 K48 连接的去泛素化直接与去泛素化并稳定过氧化物酶体增殖物激活受体 γ (PPARγ),进而稳定乙酰辅酶 A 羧化酶 (ACC) 和三磷酸柠檬酸裂解酶 (ACLY) 的表达。此外,我们发现 USP22 促进从头脂肪酸合成,并有助于 HCC 肿瘤发生,但通过在体内肿瘤发生实验中抑制 PPARγ、ACLY 或 ACC 的表达,这种致瘤性受到抑制。在 HCC 中,USP22 的高表达与 PPARγ、ACLY 或 ACC 的表达呈正相关,并与预后不良相关。总之,我们确定了一个 USP22 调节的脂肪生成机制,该机制涉及 HCC 肿瘤发生中的 PPARγ-ACLY/ACC 轴,并为通过 USP22 抑制靶向脂肪生成提供了依据。